Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1985-9-26
|
pubmed:abstractText |
102 patients with AML (leukemia after preleukemia, 2nd neoplasia included) were treated for remission induction by a modified TAD regimen in Munster; 55 patients (54%) achieved a complete remission (CR). For CR maintenance 40 patients were eligible for randomization according to the study protocol: cyclic chemotherapy (CT) alone vs. chemoimmunotherapy (CIT: plus allogeneic Neuraminidase-treated blasts in high dosage). 5 CR patients, induced identically in Essen, were randomized additionally. Evaluating all patients randomized there is only a marginally beneficial effect of CIT (21 patients) compared to CT (24 patients) concerning median survival (1020+ vs. 612 days) and relapse-free survival (494 vs. 380 days) until now. For patients receiving more than 2 cycles of maintenance therapy, however, CIT prolongs relapse-free survival significantly (930+ vs. 409 days; p = 0,02); that is also true for remission duration. This suggests that only repeated application of blasts may induce an immune response leading to a biologically relevant antileukemic effect.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0378-584X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
8
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
157-9
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:3895098-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:3895098-Bone Marrow Transplantation,
pubmed-meshheading:3895098-Combined Modality Therapy,
pubmed-meshheading:3895098-Cyclophosphamide,
pubmed-meshheading:3895098-Cytarabine,
pubmed-meshheading:3895098-Daunorubicin,
pubmed-meshheading:3895098-Drug Administration Schedule,
pubmed-meshheading:3895098-Humans,
pubmed-meshheading:3895098-Immunotherapy,
pubmed-meshheading:3895098-Leukemia, Myeloid, Acute,
pubmed-meshheading:3895098-Prospective Studies,
pubmed-meshheading:3895098-Random Allocation,
pubmed-meshheading:3895098-Thioguanine
|
pubmed:year |
1985
|
pubmed:articleTitle |
Immunotherapy with allogeneic neuraminidase-treated blasts for maintenance in acute myelogenous leukemia (AML). Significant prolongation of remission duration in patients receiving at least 3 cycles of therapy.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|